Search
Close this search box.
Search

Computer models can help predict adverse drug reactions

New computer models developed by North Carolina State University could allow researchers to better understand and predict adverse drug reactions. Researchers from the University have used the models to show what happens at the molecular level during severe allergic reactions to abacavir, a common HIV drug. In the future these models could be used for all sorts of drugs.

New computer models from North Carolina State University (NYSU) show how a variant of a common protein involved in human immune response binds to the antiviral drug abacavir, causing a severe life-threatening reaction known as the abacavir hypersensitivity syndrome (AHS). The work has implications for predicting severe adverse reactions caused by existing drugs and future drug candidates in subpopulations of patients.

Abacavir is a common anti-HIV drug. However, it is associated with severe allergic reactions in a fraction (5-8 percent) of patients who take it. Previous research determined that this response occurs in patients with a particular variant of a human leukocyte antigen (HLA) known as HLA-B*57:01. Denis Fourches, assistant professor of chemistry at NC State, and his graduate student, George Van Den Driessche, wanted to know what happens at the molecular level when abacavir and other drugs interact with HLA-B*57:01.

Their research has been published in the Journal of Cheminformatics, and was funded by the NC State Chancellor’s Faculty Excellence Program. Van Den Driessche is first author of the paper, Fourches is the corresponding author.

Triggering immune response

HLA proteins reside on the surface of cells. They help the immune system distinguish between its own proteins and those made by infectious agents. HLA proteins and their co-binding peptides serve as signaling proteins that communicate with T-cells, ensuring all is well. If something foreign – a pathogen or a drug like abacavir – binds to the HLA protein, displacing the co-binding peptide and deforming the overall shape of the molecular complex, this change is recognized by immune cells, triggering the immune response.

There are 15,000 variants of HLA, and everyone carries some of these variants. HLA-B*57:01 is one of the first variants studied in the context of a drug-induced immune reactions. It binds with abacavir, but little was understood about exactly what was happening structurally at the molecular level, especially in terms of the relationship with the co-binding peptide.

Series of computer models

To better understand this complex system, Fourches and Van Den Driessche created a series of computer models using three-dimensional molecular docking that allowed them to look at the ways in which abacavir docks in the binding site of HLA-B*57:01 – where the co-binding peptide normally docks. The models incorporated 3D structures of abacavir, HLA-B*57:01, and several potential co-binding peptides. The researchers ran molecular modeling simulations to virtually dock abacavir in the HLA-B*57:01 active site in the absence and presence of a co-binding peptide. Finally, they virtually screened an additional set of 13 drugs, some of which are known to cause severe adverse responses that are also suspected of being linked to HLA variants.

“The models allowed us to identify key atomic interactions that cause abacavir and other drugs to bind to the HLA variant protein and ultimately trigger the immune response,” Fourches explains. “When you can forecast and understand the elements of the drug that enable the binding to occur, you may be able to create new active compounds that do not have that problem.”

The researchers’ ultimate goal is to use molecular modeling to discover and understand how different drugs can interact with the immune system via direct HLA binding interaction, so that better predictions of the side-effects of new drugs and designing drugs with fewer side-effects becomes possible. This, the researchers believe, is critical for the personalized medicine of tomorrow.

Whixx

ICT&health World Conference 2024

Experience the future of healthcare at the ICT&health World Conference from May 14th to 16th, 2024!
Secure your ticket now and immerse yourself in groundbreaking technologies and innovative solutions.
Engage with fellow experts and explore the power of global collaborations.

Share this article!

Read also
Balancing regulatory compliance with seamless adoption, healthcare navigates the integration of AI solutions.
A guide to implementing AI in healthcare amid the EU AI Act
AmyWebb-Stephen-Olker
Futurist Amy Webb claims that wearables will evolve into "connectables"
Digital health solutions empower patients to better manage their health and integrate care into their daily lives.
How to improve Digital Patient Engagement to streamline workflows
For people with diabetes, inaccurate blood glucose measurements can lead to errors in diabetes management, including taking the wrong dose of insulin, sulfonylureas, or other medications that can rapidly lower blood glucose.
Smartwatches measuring glucose level: Harmful but easy to buy fake innovations
How to introduce innovation and AI in healthcare organizations if there is no business model for prevention and quality – Our interview with Professor Ran Balicer, the Chief Innovation Officer at Clalit Health Services and founding Director of Clalit Research Institute.
I see no legitimate rationale for delaying the digital transformation in healthcare
Pioneering Cardiac Arrest Detection for Enhanced Survival.
CardioWatch Revolutionizes Cardiac Arrest Detection
Dr. Oscar Díaz-Cambronero, Head of Perioperative Medicine Department at La Fe Hospital, spearheads innovative telemonitoring initiatives revolutionizing patient care
Smartwatches Saving Lives Inside and Outside the Hospital
EIT 2024
EIT Awards 2024. Two European startups are revolutionizing the treatment of cardiovascular diseases
Bertrand Piccard, Swiss explorer and founder of the Solar Impulse Foundation
EIT Summit 2024. What are the trigger points that drive or inhibit innovation?
MMC pioneers wireless monitoring for premature infants with the innovative Bambi Belt, revolutionizing care with improved comfort and mobility.
Wireless Monitoring of Vital Signs in Premature Infants at Máxima MC
Follow us